达主要终点-话题@MedSci

#达主要终点#

23篇内容 | 494人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1813835, encodeId=500e181383565, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, objectType=article, longId=192692, objectId=46461926922a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46461926922a, replyNumber=0, likeNumber=47, createdTime=2020-06-17, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46461926922a, moduleTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46461926922a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813834, encodeId=55ef1813834bd, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), objectType=article, longId=106852, objectId=5c6a10685217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c6a10685217, replyNumber=0, likeNumber=39, createdTime=2018-04-10, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c6a10685217, moduleTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c6a10685217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813833, encodeId=2221181383393, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=膀胱癌药物3期临床达主要终点, objectType=article, longId=100370, objectId=138c1003e005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=138c1003e005, replyNumber=0, likeNumber=0, createdTime=2017-07-02, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=138c1003e005, moduleTitle=膀胱癌药物3期临床达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=138c1003e005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813832, encodeId=b46f18138328c, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=艾滋病新复方药3期临床试验达主要终点, objectType=article, longId=85189, objectId=47ed85189ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47ed85189ef, replyNumber=0, likeNumber=33, createdTime=2017-03-08, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47ed85189ef, moduleTitle=艾滋病新复方药3期临床试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47ed85189ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813831, encodeId=b73d1813831e8, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, objectType=article, longId=55957, objectId=68175595eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68175595eff, replyNumber=0, likeNumber=32, createdTime=2015-09-10, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68175595eff, moduleTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68175595eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813825, encodeId=87641813825db, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=拜耳多吉美（Nexavar）肝癌III期未达主要终点, objectType=article, longId=31832, objectId=f1413183272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1413183272, replyNumber=0, likeNumber=48, createdTime=2014-09-03, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1413183272, moduleTitle=拜耳多吉美（Nexavar）肝癌III期未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1413183272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813824, encodeId=ee2c181382435, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=默沙东Isentress大规模III期研究达主要终点, objectType=article, longId=31742, objectId=ba9a31e42bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba9a31e42bc, replyNumber=0, likeNumber=38, createdTime=2014-09-30, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba9a31e42bc, moduleTitle=默沙东Isentress大规模III期研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba9a31e42bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813822, encodeId=5514181382287, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=辉瑞疫苗Prevenar13用于老年患者研究达主要终点, objectType=article, longId=31343, objectId=1b11313436b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b11313436b, replyNumber=0, likeNumber=0, createdTime=2015-01-17, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b11313436b, moduleTitle=辉瑞疫苗Prevenar13用于老年患者研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b11313436b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813830, encodeId=f90d1813830e9, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=GSK单抗药Arzerra III期CLL研究未达主要终点, objectType=article, longId=37293, objectId=aa053e2935e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa053e2935e, replyNumber=0, likeNumber=42, createdTime=2015-05-03, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa053e2935e, moduleTitle=GSK单抗药Arzerra III期CLL研究未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa053e2935e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813827, encodeId=0c9e181382e64, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=吉利德丙肝新药Sovaldi日本III期试验达主要终点, objectType=article, longId=33000, objectId=3fca33000a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fca33000a7, replyNumber=0, likeNumber=29, createdTime=2014-05-26, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fca33000a7, moduleTitle=吉利德丙肝新药Sovaldi日本III期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fca33000a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813817, encodeId=2cdf181381eaf, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, objectType=article, longId=25824, objectId=c92d2582476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c92d2582476, replyNumber=0, likeNumber=41, createdTime=2014-09-27, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c92d2582476, moduleTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c92d2582476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813816, encodeId=bc101813816b5, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, objectType=article, longId=25277, objectId=4107252e7fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4107252e7fd, replyNumber=0, likeNumber=37, createdTime=2014-08-24, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4107252e7fd, moduleTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4107252e7fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813820, encodeId=fa0a181382066, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=辉瑞戒烟药varenicline新研究达主要终点, objectType=article, longId=29874, objectId=8ed5298e4cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ed5298e4cb, replyNumber=0, likeNumber=26, createdTime=2014-07-22, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ed5298e4cb, moduleTitle=辉瑞戒烟药varenicline新研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ed5298e4cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813828, encodeId=18a018138280f, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, objectType=article, longId=33003, objectId=65bc330037a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65bc330037a, replyNumber=0, likeNumber=31, createdTime=2014-08-27, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65bc330037a, moduleTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65bc330037a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813826, encodeId=c3c2181382636, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, objectType=article, longId=32022, objectId=e7cc32022c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7cc32022c7, replyNumber=0, likeNumber=37, createdTime=2014-06-11, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7cc32022c7, moduleTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7cc32022c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813815, encodeId=108a181381570, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, objectType=article, longId=22742, objectId=237922e4273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237922e4273, replyNumber=0, likeNumber=36, createdTime=2013-09-23, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237922e4273, moduleTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237922e4273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813821, encodeId=6187181382106, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=诺华抗癌药LDE225关键性BOLT研究达主要终点, objectType=article, longId=30912, objectId=3e72309122a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e72309122a, replyNumber=0, likeNumber=0, createdTime=2014-04-26, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e72309122a, moduleTitle=诺华抗癌药LDE225关键性BOLT研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e72309122a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813818, encodeId=9b2c181381821, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=GSK冠心病药物darapladibIII期研究未达主要终点, objectType=article, longId=26582, objectId=49d2265824c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49d2265824c, replyNumber=0, likeNumber=31, createdTime=2013-12-21, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49d2265824c, moduleTitle=GSK冠心病药物darapladibIII期研究未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49d2265824c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813829, encodeId=a3c6181382925, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=阿斯利康2种治疗自身免疫性疾病的单抗药物II期研究均达主要终点, objectType=article, longId=34818, objectId=075d3481802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=075d3481802, replyNumber=0, likeNumber=30, createdTime=2014-10-01, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=075d3481802, moduleTitle=阿斯利康2种治疗自身免疫性疾病的单抗药物II期研究均达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=075d3481802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813813, encodeId=2913181381381, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, objectTitle=Pacira制药Exparel III期肋间神经阻滞试验未达主要终点, objectType=article, longId=22664, objectId=6d64226640b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d64226640b, replyNumber=0, likeNumber=0, createdTime=2014-05-14, rootId=0, userName=陈吴1234, userId=cbf451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d64226640b, moduleTitle=Pacira制药Exparel III期肋间神经阻滞试验未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d64226640b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达主要终点

2020-05-29

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点

2020-06-17

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究)

2018-04-10

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

膀胱癌药物3期临床达主要终点

2017-07-02

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

艾滋病新复方药3期临床试验达主要终点

2017-03-08

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案

2015-09-10

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

拜耳多吉美（Nexavar）肝癌III期未达主要终点

2014-09-03

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

默沙东Isentress大规模III期研究达主要终点

2014-09-30

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

辉瑞疫苗Prevenar13用于老年患者研究达主要终点

2015-01-17

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

GSK单抗药Arzerra III期CLL研究未达主要终点

2015-05-03

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

吉利德丙肝新药Sovaldi日本III期试验达主要终点

2014-05-26

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点

2014-09-27

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点

2014-08-24

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

辉瑞戒烟药varenicline新研究达主要终点

2014-07-22

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

辉瑞CDK4/6抑制剂palbociclib II期达主要终点

2014-08-27

一叶知秋 (审核中...)

前往app查看评论内容

#达主要终点#

安进PCSK9抑制剂evolocumab III期TESLA达主要终点

2014-06-11

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点

2013-09-23

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

诺华抗癌药LDE225关键性BOLT研究达主要终点

2014-04-26

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

GSK冠心病药物darapladibIII期研究未达主要终点

2013-12-21

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

阿斯利康2种治疗自身免疫性疾病的单抗药物II期研究均达主要终点

2014-10-01

陈吴1234 (审核中...)

前往app查看评论内容

#达主要终点#

Pacira制药Exparel III期肋间神经阻滞试验未达主要终点

2014-05-14

科室
- - 订阅+
  - 更多科室
工具
服务